Angiotensin converting enzyme inhibitors and lung cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies.Cancer cell international · 2023
   Review
2. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study.British journal of cancer · 2022
   Article
3. Risk of lung cancer and renin-angiotensin blockade: a concise review.Journal of cancer research and clinical oncology · 2021
   Review
4. The role of the renin-angiotensin system inhibitors in malignancy: a review.American journal of cancer research · 2021
   Review
5. Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension.PeerJ · 2019
   Article

Corrections and comments

• Comment on
  Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as